Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) PT at $19.00

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $19.00.

A number of research analysts have weighed in on ARTV shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th. Finally, HC Wainwright lifted their price target on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. OMERS ADMINISTRATION Corp bought a new position in shares of Artiva Biotherapeutics during the fourth quarter valued at approximately $91,000. Marshall Wace LLP bought a new stake in shares of Artiva Biotherapeutics during the 4th quarter worth approximately $341,000. Jane Street Group LLC purchased a new position in Artiva Biotherapeutics during the 4th quarter valued at $174,000. Renaissance Technologies LLC boosted its holdings in Artiva Biotherapeutics by 46.8% during the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock valued at $498,000 after acquiring an additional 37,053 shares during the period. Finally, Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics in the 3rd quarter valued at $41,000.

Artiva Biotherapeutics Stock Performance

NASDAQ:ARTV opened at $5.74 on Monday. The stock’s fifty day moving average is $4.56 and its 200 day moving average is $3.84. Artiva Biotherapeutics has a fifty-two week low of $1.47 and a fifty-two week high of $7.36. The firm has a market capitalization of $140.92 million, a PE ratio of -2.22 and a beta of 2.16.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.